Cost-Effectiveness Study of Initial Imaging Selection in Acute Ischemic Stroke Care

J Am Coll Radiol. 2021 Jun;18(6):820-833. doi: 10.1016/j.jacr.2020.12.013. Epub 2020 Dec 30.

Abstract

Purpose: National guidelines recommend prompt identification of candidates for acute ischemic stroke (AIS) treatment, requiring timely neuroimaging with CT and/or MRI. CT is often preferred because of its widespread availability and rapid acquisition. Despite higher diagnostic accuracy of MRI, it commonly involves complex workflows that could potentially cause treatment time delays. The purpose of this study was to analyze the impact on outcomes of imaging utilization before treatment decisions at comprehensive stroke centers for patients presenting with suspected AIS in the anterior circulation with last-known-well-to-arrival time 0 to 24 hours.

Methods: A decision simulation model based on the American Heart Association's recommendations for AIS care pathways was developed from a health care perspective to compare initial imaging strategies: (1) stepwise-CT: noncontrast CT (NCCT) at the time of presentation, with CT angiography (CTA) ± CT perfusion (CTP) only in select patients (initial imaging to exclude hemorrhage and extensive ischemia) for mechanical thrombectomy (MT) evaluation; (2) stepwise-hybrid: NCCT at the time of presentation, with MR angiography (MRA) ± MR perfusion (MRP) only for MT evaluation; (3) stepwise-advanced: NCCT + CTA at presentation, with MR diffusion-weighted imaging (MR DWI) + MRP only for MT evaluation; (4) comprehensive-CT: NCCT + CTA + CTP at the time of presentation; and (5) comprehensive-MR: MR DWI + MRA + MRP at the time of presentation. Model parameters were defined using evidence-based data. Cost-effectiveness and sensitivity analyses were performed.

Results: The cost-effectiveness analyses revealed that comprehensive-CT and comprehensive-MR yield the highest lifetime quality-adjusted life-years (QALYs) (4.81 and 4.82, respectively). However, the incremental cost-effectiveness ratio of comprehensive-MR is $233,000/QALY compared with comprehensive-CT. Stepwise-CT, stepwise-hybrid, and stepwise-advanced strategies are dominated, yielding lower QALYs and higher costs compared with comprehensive-CT.

Conclusions: Performing comprehensive-CT at presentation is the most cost-effective initial imaging strategy at comprehensive stroke centers.

Keywords: Cost-effectiveness; acute ischemic stroke imaging; advanced neuroimaging.

MeSH terms

  • Brain Ischemia* / diagnostic imaging
  • Brain Ischemia* / therapy
  • Cost-Benefit Analysis
  • Diffusion Magnetic Resonance Imaging
  • Humans
  • Ischemic Stroke*
  • Stroke* / diagnostic imaging
  • Stroke* / therapy